Outlook Therapeutics Announces Formal Dispute Resolution Meeting with FDA for ONS-5010/LYTENAVA™

Key Highlights

• Outlook Therapeutics (Nasdaq: OTLK) has submitted a Formal Dispute Resolution Request (FDRR) to the FDA following a Complete Response Letter (CRL) for its ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA).
• The FDA has accepted the dispute resolution request and scheduled a meeting with the deciding official for April 2026.
• The company is advocating that data from its pivotal clinical trials, NORSE TWO and NORSE EIGHT, are sufficient to support approval for the treatment of neovascular age-related macular degeneration (wet AMD).
• ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab if approved, with an established U.S. supply chain and FDA-compliant manufacturing.
• Regulatory status: Already received Marketing Authorization in the EU and UK, and commercial launch has commenced in Austria and the UK.

Detailed Investor Summary

Outlook Therapeutics, Inc. has taken a decisive regulatory step with the FDA to advance its lead candidate ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of wet AMD, a leading cause of blindness. Following the FDA’s issuance of a Complete Response Letter (CRL) on December 30, 2025, the company engaged in a formal Type A meeting with the FDA in March 2026, which led to the filing of a Formal Dispute Resolution Request (FDRR). The FDA has now accepted the company’s FDRR and scheduled a meeting with the deciding official in April 2026. This process could be pivotal in determining the future approval prospects of ONS-5010 in the U.S.

Pivotal Clinical Data and Supporting Arguments

• Outlook Therapeutics is emphasizing the strength of the data from its NORSE TWO (randomized, double-masked, active-controlled Phase 3 trial) and NORSE EIGHT studies. These studies demonstrated clinically meaningful and statistically significant improvements in visual acuity, meeting both primary and key secondary endpoints.
• The company highlights that additional clinical, functional, pharmacodynamic, and safety data were submitted, reinforcing the efficacy and safety profile of ONS-5010/LYTENAVA™. Notably, the FDA has not raised any safety concerns regarding the product.
• If approved, ONS-5010/LYTENAVA™ would become the first FDA-approved, ophthalmic-specific bevacizumab with standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance, addressing long-standing concerns over off-label use of oncology formulations in ophthalmology.

Regulatory and Commercial Status

• In Europe, the product (bevacizumab gamma) has received centralized Marketing Authorization from the European Commission and the UK’s MHRA for wet AMD. Commercial launches have begun in Austria and the UK.
• In the U.S., ONS-5010/LYTENAVA™ remains investigational. Approval would provide the first FDA-sanctioned use of bevacizumab for retinal diseases, potentially making it a preferred choice over compounded alternatives.
• The product is supported by a fully domestic, end-to-end U.S. manufacturing supply chain, which may be viewed as favorable amid ongoing concerns about supply chain security and pharmaceutical quality.

Potential Price-Sensitive and Shareholder-Relevant Information

• This FDRR process and upcoming FDA meeting represent a major regulatory inflection point. A positive outcome could lead to U.S. approval, opening a large market and potentially driving significant revenue, while a negative outcome might result in further delays or require additional studies.
• The company’s assertion that no safety concerns have been raised and that efficacy was established in pivotal trials positions ONS-5010/LYTENAVA™ as a strong candidate for approval, which could meaningfully impact the company’s valuation and share price.
• The product’s regulatory success in Europe and commercial launch momentum may provide additional validation and revenue streams, enhancing investor confidence.

Forward-Looking Statements and Risks

Investors should note the company’s caution that forward-looking statements are subject to substantial risks and uncertainties, including but not limited to the outcomes of regulatory reviews, the need for additional data or studies, the timing of FDA decisions, and broader macroeconomic factors such as inflation and global trade tensions. These risks could materially affect future results and share value.

Contact Information

Investor Inquiries:
Jenene Thomas, Chief Executive Officer, JTC Team, LLC
T: 908.824.0775
Email: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those anticipated.

View Outlook Therapeutics, Inc. Historical chart here